MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
CAMBRIDGE, Mass., March 11, 2024 – MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced that Jullian G. Jones,Ph.D., J.D., MBA, has been appointed as the company’s chief business officer. In this role, Dr. Jones will be responsible for guiding MOMA’s corporate and business strategy, which includes investor relations, business development, new product planning, and oversight of strategic finance and accounting.
“We are thrilled to welcome Jullian to MOMA. She has an exceptional track record of thinking and acting strategically and creatively across different business dimensions, while leading with heart and a passion for mentorship,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA. “Jullian’s expertise is perfectly aligned with MOMA’s business needs at this stage of our growth and positions us more strongly for success. This will be a busy year as we anticipate filing Investigational New Drug applications with the FDA for our two lead programs.”
A seasoned business development executive with more than 15 years of life sciences and pharmaceutical industry experience, Dr. Jones joins MOMA from Monte Rosa Therapeutics, Inc. where she most recently served as chief business officer. In that role, she led business development and early commercial strategy and competitive insights for portfolio programs and played a pivotal role in developing the company’s pipeline. Dr. Jones also oversaw the company’s strategic partnership with Roche Pharmaceuticals, as well as multiple collaborations with external partners that enhanced Monte Rosa’s platform capabilities. Previously, as SVP, head of business development, Dr. Jones’ business and financial acumen were integral as a part of the team that lead to Monte Rosa’s upsized IPO in 2021.
“The caliber of MOMA’s science and talent is unmatched, and I enthusiastically share our collective mission to take on difficult-to-drug, highly dynamic proteins at the root of many diseases, including cancer,” said Dr. Jones. “I look forward to collaborating with and learning from MOMA team members across functions as we work together to advance transformative precision medicines for patients in the near- and long-term.”
Prior to Monte Rosa, Dr. Jones served as senior director of oncology business development at Eli Lilly and Company, leading the identification and strategic assessment of cross-portfolio in-licensing, out-licensing, and M&A opportunities for the Oncology Therapeutic Area, including the $8 billion acquisition of Loxo Oncology. Previously, she served in several leadership roles at Boehringer Ingelheim, including business development and licensing, global marketing, and new product planning. She began her life sciences business development career at Columbia Technology Ventures, responsible for licensing early life sciences technologies and facilitating the spin-off of early-phase companies. Dr. Jones holds a Ph.D. from Johns Hopkins University, a J.D. from Georgetown University Law Center, and an MBA from Colombia University.
About MOMA Therapeutics
MOMA Therapeutics is committed to discovering the next generation of precision medicines by targeting highly dynamic proteins that underlie human disease. Bringing together seminal scientific advancements in biochemistry, biophysics, structural biology, chemistry, computation, and functional genomics, the company has established the KnowledgeBase platform to exploit a key vulnerability inherent to all dynamic proteins: their dependence on well-coordinated, stepwise changes in protein conformation. By focusing this platform on disease-causing targets, MOMA aims to develop high impact, precision medicines for patients with unmet medical needs. MOMA Therapeutics is a private company launched in 2020 with seasoned leadership, a highly specialized workforce with deep expertise in oncology discovery, world-class scientific founders, and financed by leading biotech investors.
As part of its ongoing commitment to precision oncology research and development, MOMA is also prosecuting two lead programs at development candidate stage, for which it anticipates filing Investigational New Drug (IND) applications with the U.S. Food and Drug Administration in 2024. These assets, along with multiple earlier projects, comprise MOMA’s wholly owned portfolio.
Media Contact
Katie Engleman, 1AB